Biotricity, Inc. (BTCY)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Biotricity, Inc. (BTCY) with AI Score 52/100 (Hold). Biotricity, Inc. is a medical technology company focused on providing remote biometric data monitoring solutions. Their primary focus is on diagnostic and post-diagnostic solutions for chronic illnesses. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Biotricity, Inc. (BTCY) Healthcare & Pipeline Overview
Biotricity, Inc. delivers remote biometric data monitoring solutions, primarily in the United States, focusing on diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. Its Bioflux mobile cardiac telemetry solution and ECG analysis software position it in the competitive medical device market, serving medical, healthcare, and consumer segments.
Investment Thesis
Biotricity operates in the expanding remote patient monitoring market, driven by an aging population and increasing prevalence of chronic diseases. The company's Bioflux solution and ECG analysis software offer a comprehensive approach to cardiac monitoring, potentially reducing hospital readmissions and improving patient care. With a market capitalization of $0.01 billion, Biotricity's growth hinges on expanding its market share and securing regulatory approvals for new products. A gross margin of 81.1% indicates strong pricing power, but profitability remains a challenge with a negative P/E ratio of -1.83 and a negative profit margin of -26.0%. Key value drivers include increasing adoption of remote monitoring technologies, strategic partnerships with healthcare providers, and successful commercialization of its product pipeline. Investors should monitor the company's ability to achieve profitability and manage its cash flow effectively.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $0.01 billion reflects its position as a micro-cap company.
- Gross Margin of 81.1% indicates strong potential for profitability if sales volume increases.
- Negative P/E ratio of -1.83 suggests the company is currently not profitable.
- Profit Margin of -26.0% highlights the need for improved cost management and revenue growth.
- Beta of 1.40 indicates higher volatility compared to the overall market.
Competitors & Peers
Strengths
- Proprietary Bioflux mobile cardiac telemetry solution.
- ECG analysis software provides actionable insights.
- Focus on remote monitoring aligns with market trends.
- High gross margin of 81.1%.
Weaknesses
- Negative P/E ratio indicates lack of profitability.
- Limited market share compared to larger competitors.
- Reliance on a single product line (Bioflux).
- OTC market listing may limit investor access.
Catalysts
- Ongoing: Expansion of Bioflux sales into new geographic markets.
- Ongoing: Development of new remote monitoring solutions for other chronic conditions.
- Ongoing: Strategic partnerships with healthcare providers to integrate Bioflux into their workflows.
- Upcoming: Potential FDA approval for new product features or enhancements.
- Ongoing: Integration of Bioflux with telehealth platforms to expand reach.
Risks
- Potential: Competition from larger, more established medical device companies.
- Potential: Regulatory hurdles and delays in FDA approval processes.
- Potential: Reimbursement challenges from insurance providers for remote monitoring services.
- Ongoing: Dependence on a single product line (Bioflux).
- Ongoing: Limited financial resources to support growth initiatives.
Growth Opportunities
- Expansion of Bioflux into New Markets: Biotricity has the opportunity to expand the market reach of its Bioflux mobile cardiac telemetry solution beyond the United States. The global remote patient monitoring market is projected to reach $175.2 billion by 2027, presenting a significant opportunity for Biotricity to increase its revenue streams. This expansion could involve strategic partnerships with international distributors and adaptation of the Bioflux solution to meet local regulatory requirements. Timeline: 2-3 years.
- Development of New Remote Monitoring Solutions: Biotricity can leverage its expertise in biometric data monitoring to develop new remote monitoring solutions for other chronic conditions, such as diabetes and respiratory diseases. The market for remote monitoring of diabetes is expected to grow significantly in the coming years, driven by the increasing prevalence of the disease. By diversifying its product portfolio, Biotricity can reduce its reliance on cardiac monitoring and tap into new revenue streams. Timeline: 3-5 years.
- Strategic Partnerships with Healthcare Providers: Biotricity can form strategic partnerships with healthcare providers, such as hospitals and clinics, to integrate its Bioflux solution into their existing workflows. These partnerships can provide Biotricity with access to a large patient base and increase the adoption of its products. The healthcare industry is increasingly embracing remote patient monitoring as a way to improve patient outcomes and reduce costs. Timeline: Ongoing.
- Integration with Telehealth Platforms: Biotricity can integrate its Bioflux solution with telehealth platforms to provide patients with remote access to healthcare professionals. The telehealth market is experiencing rapid growth, driven by the increasing demand for convenient and accessible healthcare services. By integrating with telehealth platforms, Biotricity can expand its reach and provide patients with a more comprehensive healthcare experience. Timeline: 1-2 years.
- Leveraging AI and Machine Learning: Biotricity can leverage artificial intelligence (AI) and machine learning (ML) to enhance its ECG analysis software and provide more accurate and personalized insights to healthcare professionals. AI and ML can be used to identify patterns in patient data and predict potential health issues before they occur. This can improve patient outcomes and reduce the burden on healthcare systems. Timeline: Ongoing.
Opportunities
- Expansion into new geographic markets.
- Development of new remote monitoring solutions for other chronic conditions.
- Strategic partnerships with healthcare providers.
- Integration with telehealth platforms.
Threats
- Competition from established medical device companies.
- Regulatory hurdles and FDA approval processes.
- Reimbursement challenges from insurance providers.
- Technological advancements by competitors.
Competitive Advantages
- Proprietary ECG analysis software.
- Integrated Bioflux mobile cardiac telemetry solution.
- Focus on remote monitoring solutions for chronic illnesses.
- Established relationships with healthcare providers.
About BTCY
Biotricity, Inc., established as a medical technology company, specializes in biometric data monitoring solutions within the United States. The company's core mission revolves around providing remote monitoring solutions tailored for medical, healthcare, and consumer markets, with a particular emphasis on diagnostic and post-diagnostic applications for lifestyle-related and chronic illnesses. Biotricity's flagship product is the Bioflux mobile cardiac telemetry solution, an integrated ECG device designed for continuous heart monitoring. Complementing this hardware is their proprietary ECG analysis software, which analyzes and synthesizes patient ECG monitoring data to provide actionable insights for healthcare professionals. The company's solutions aim to improve patient outcomes and reduce healthcare costs through proactive monitoring and early detection of potential health issues. Headquartered in Redwood City, California, Biotricity is strategically located in a hub of technological innovation, allowing it to attract talent and foster partnerships within the medical technology ecosystem. The company continues to evolve its product offerings to address the growing demand for remote patient monitoring solutions.
What They Do
- Develop and market the Bioflux mobile cardiac telemetry solution.
- Provide ECG analysis software for synthesizing patient ECG monitoring data.
- Offer remote monitoring solutions for medical, healthcare, and consumer markets.
- Focus on diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses.
- Provide solutions for continuous heart monitoring.
- Offer software components for analyzing ECG data.
Business Model
- Sales of Bioflux mobile cardiac telemetry devices.
- Subscription fees for ECG analysis software.
- Partnerships with healthcare providers for remote patient monitoring services.
Industry Context
Biotricity operates within the medical device industry, specifically in the remote patient monitoring (RPM) market. This market is experiencing rapid growth, driven by factors such as the aging population, increasing prevalence of chronic diseases, and advancements in wearable technology. The competitive landscape includes established medical device companies and emerging technology startups. Biotricity's focus on cardiac monitoring positions it within a niche segment of the RPM market. The industry is also subject to stringent regulatory requirements, including FDA approvals and data privacy regulations.
Key Customers
- Hospitals and clinics.
- Healthcare providers.
- Patients with chronic illnesses.
- Consumers seeking remote health monitoring solutions.
Financials
Chart & Info
Biotricity, Inc. (BTCY) stock price: Price data unavailable
Latest News
-
Earnings Scheduled For November 14, 2023
benzinga · Nov 14, 2023
-
Earnings Scheduled For February 14, 2023
benzinga · Feb 14, 2023
-
Stocks That Hit 52-Week Lows On Tuesday
benzinga · Apr 26, 2022
-
Stocks That Hit 52-Week Lows On Monday
benzinga · Apr 25, 2022
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BTCY.
Price Targets
Wall Street price target analysis for BTCY.
MoonshotScore
What does this score mean?
The MoonshotScore rates BTCY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Waqaas Al-Siddiq
CEO
Waqaas Al-Siddiq serves as the CEO of Biotricity, Inc., leading a team of 55 employees. His background encompasses a blend of technology and business acumen, positioning him to steer the company's strategic direction. He has experience in managing and scaling technology-driven healthcare solutions, with a focus on remote patient monitoring and data analytics. His expertise is crucial for navigating the complexities of the medical device industry and driving innovation within Biotricity.
Track Record: Under Waqaas Al-Siddiq's leadership, Biotricity has focused on the development and commercialization of its Bioflux mobile cardiac telemetry solution. He has overseen the company's efforts to secure regulatory approvals and establish partnerships with healthcare providers. Key milestones include expanding the product's market reach and enhancing the ECG analysis software capabilities. His strategic decisions aim to position Biotricity as a leader in the remote cardiac monitoring space.
BTCY OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Biotricity may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and operational performance. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face fewer regulatory requirements and may have higher risks associated with transparency and governance.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure due to OTC Other tier listing.
- Higher price volatility due to lower trading volume.
- Potential for fraud or manipulation in the OTC market.
- Limited regulatory oversight compared to major exchanges.
- Difficulty in obtaining accurate and timely information about the company.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance and legal risks.
- Check for any history of fraud or misconduct.
- Monitor trading volume and price volatility.
- Consult with a qualified financial advisor.
- Existence of a functional website and contact information.
- Presence of a physical headquarters and operational facilities.
- Patents or trademarks related to its products or services.
- Partnerships with reputable healthcare providers.
- Positive media coverage or industry recognition.
BTCY Healthcare Stock FAQ
What does Biotricity, Inc. do?
Biotricity, Inc. is a medical technology company that specializes in providing remote biometric data monitoring solutions. Its primary product, the Bioflux mobile cardiac telemetry solution, is an integrated ECG device used for continuous heart monitoring. The company also offers ECG analysis software that analyzes and synthesizes patient ECG monitoring data. Biotricity focuses on delivering diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses, serving medical, healthcare, and consumer markets in the United States. The company's goal is to improve patient outcomes and reduce healthcare costs through proactive monitoring and early detection.
What do analysts say about BTCY stock?
As of 2026-03-16, a comprehensive analyst consensus for BTCY is not available due to its OTC listing and limited coverage. Key valuation metrics such as price targets and earnings estimates may not be readily accessible. Investors may want to evaluate the company's growth potential in the remote patient monitoring market, its financial performance (including gross margin and profitability), and the risks associated with its OTC listing. Further independent research and due diligence are recommended before making any investment decisions.
What are the main risks for BTCY?
Biotricity faces several risks, including competition from larger medical device companies, regulatory hurdles and FDA approval processes, and reimbursement challenges from insurance providers for remote monitoring services. The company's dependence on a single product line (Bioflux) and its limited financial resources also pose significant risks. Additionally, its OTC listing exposes investors to higher price volatility and limited liquidity. Successful mitigation of these risks is crucial for Biotricity's long-term growth and sustainability.
What are the key factors to evaluate for BTCY?
Biotricity, Inc. (BTCY) currently holds an AI score of 52/100, indicating moderate score. Key strength: Proprietary Bioflux mobile cardiac telemetry solution.. Primary risk to monitor: Potential: Competition from larger, more established medical device companies.. This is not financial advice.
How frequently does BTCY data refresh on this page?
BTCY prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven BTCY's recent stock price performance?
Recent price movement in Biotricity, Inc. (BTCY) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary Bioflux mobile cardiac telemetry solution.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider BTCY overvalued or undervalued right now?
Determining whether Biotricity, Inc. (BTCY) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying BTCY?
Before investing in Biotricity, Inc. (BTCY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available due to OTC listing.
- AI analysis pending for BTCY.